相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
Susan M. O'Brien et al.
BLOOD (2009)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2009)
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
Asher A. Chanan-Khan et al.
LEUKEMIA & LYMPHOMA (2009)
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
Luca Paoluzzi et al.
BLOOD (2008)
Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer
Dimitra Micha et al.
CLINICAL CANCER RESEARCH (2008)
Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2008)
Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer:: CALGB 30103
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expanding circle of inhibition: Small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents
Benjamin D. Zeitlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The BCL-2 protein family: opposing activities that mediate cell death
Richard J. Youle et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Victoria Del Gaizo Moore et al.
BLOOD (2008)
Oblimersen and α-interferon in metastatic renal cancer:: a phase II study of the California Cancer Consortium
Kim Margolin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02
Li Yan Khor et al.
CLINICAL CANCER RESEARCH (2007)
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
Kyung-Hun Lee et al.
BMC CANCER (2007)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation
Shuang Chen et al.
CANCER RESEARCH (2007)
Larger than life: Mitochondria and the Bcl-2 family
Joanna Skommer et al.
LEUKEMIA RESEARCH (2007)
The inhibitors of apoptosis (IAPs) as cancer targets
Allison M. Hunter et al.
APOPTOSIS (2007)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (vol 103, pg 14907, 2006)
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
Junya Kuroda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice
Jill Lacy et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
(-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo
Keith G. Wolter et al.
NEOPLASIA (2006)
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer
MM Mita et al.
ANNALS OF ONCOLOGY (2006)
Investigations on gossypol: past and present developments
K Dodou
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells:: role of wild-type p53 and Bcl-XL
JA Bauer et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts
M De Cesare et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
CM Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2004)
G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma
NWCJ van de Donk et al.
LEUKEMIA (2004)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein
NWCJ van de Donk et al.
LEUKEMIA (2003)
Oblimersen bcl-2 antisense: Facilitating apoptosis in anticancer treatment
RJ Klasa et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
CM Rudin et al.
ANNALS OF ONCOLOGY (2002)
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial
C Van Poznak et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
B Jansen et al.
LANCET (2000)
Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
JS Waters et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
H Miayake et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
